US Army Extends Comment Period On Proposed Exclusive Zika Licence 27/01/2017 by Intellectual Property Watch 3 Comments Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)By Kim Treanor for Intellectual Property Watch The US Army has extended the comment period on the proposed licence to pharmaceutical company Sanofi on technology necessary to create a vaccine for the Zika virus. This is the second extension, and will permit public comments through 10 March 2017. Civil society groups and health advocates have submitted comments in opposition to the Army’s issuance of an exclusive licence to a private company, citing concerns of public spending on the research and development costs, and the potential for high price of a finished vaccine under licence (IPW, Public Health, 19 January 2017). As the technology necessary to develop the vaccine was made by the US Army with public funds, the exclusive licence would only be legal if investment to develop the actual vaccine was dependent on the company’s cooperation, Knowledge Ecology International and other public health groups argued. Members of the US Congress have also raised questions about what Sanofi’s financial contribution to development has been, in light of continued funding for clinical trials it has received from the Biomedical Advanced Research and Development Authority, KEI said on 27 January. Separately, Doctors Without Borders submitted comments this week to the US Army Medical Research and Materiel Command regarding the Department of Defense’s intent to grant an exclusive license to pharmaceutical company Sanofi for patents on a promising Zika vaccine candidate. MSF said that even though the research of this vaccine was funded by taxpayer dollars, there is no assurance that Sanofi would develop this product quickly or that it would be affordable or available for those who need it most. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "US Army Extends Comment Period On Proposed Exclusive Zika Licence" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Keith Thebeau says 28/01/2017 at 2:49 pm Inovio is the leader in Zika vaccines. Inovio should be considered for this. Reply
Daryl Samsun says 28/01/2017 at 3:34 pm This vaccine is based on attenuated version of the Zika virus. This vaccine will not be safe to give to females of child bearing ages because of obvious risks of giving them snippets of the Zika virus that may be associated with the known created neurological birth defects from Zika virus. Why are you not looking at the safest form of Zika vaccines that are furthest along the development cycle and are synthetically derived Zika vaccines that have none of the associated risks of attenuated vaccines? The Zika vaccine must be able to be given to women of child bearing ages or the Zika vaccine will be a complete waste of money and time. Will Sanofi be willing to fund a neurological birth defect fund? Sanofi’s attenuated Zika vaccine if you decide to go this route could bring a about law suites due to the birth defects that could arise from their Zika vaccine itself. Just ask yourself one question “are you willing to put your daughter’s pregnancy to the test with this attenuated Zika vaccine?” Reply
[…] Source: IP Watch The US Army has extended the comment period on the proposed licence to pharmaceutical company Sanofi on technology necessary to create a vaccine for the Zika virus. This is the second extension, and will permit public comments through 10 March… Source: US Army Extends Comment Period On Proposed Exclusive Zika Licence […] Reply